Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview

Opus Genetics

06/05/2025 13:33

Opus Genetics Inc IRD.OQ IRD.O is expected to show a rise in quarterly revenue when it reports  results on May 8 (estimated) for the period ending March 31 2025

The Durham North Carolina-based  company is expected to report a 81.1% increase in revenue to $3.099 million from $1.71 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 25 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 366.7% in the last three months. ​

Wall Street's median 12-month price target for Opus Genetics Inc is $8.00​, above​ its last closing price of $0.95. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.26
-0.22
Beat
14.3
Sep. 30 2024
-0.25
-0.24
-0.29
Missed
-22.1
Jun. 30 2024
-0.28
-0.25
-0.30
Missed
-17.6​
Mar. 31 2024
-0.11
-0.13
-0.29
Missed
-116.4
​​Dec. 31 2023
-0.03
-0.05
-0.21
Missed
-300
Sep. 30 2023
-0.24
-0.22
0.25
Beat
212.6​
Jun. 30 2023
-0.25
-0.23
-0.24
Missed
-6.2
Mar. 31 2023
-0.18
-0.15
-0.28
Missed
-81.8

This summary was machine generated May 6 at 12:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)